Hasselt University
Diepenbeek, 3590, Belgium
NCT Number: NCT02418728
In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.
The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.
Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.
Looking for future studies?
Notify Me35 year–60 year
Male
Observational
Diepenbeek, 3590, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
Time frame: week 1
abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.
Time frame: week 1
measurement systemic ANP response (venous blood sampling)
Time frame: screening
Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)
Time frame: Day 1
heart function by means of standard echocardiography
Time frame: Day 1
measured using indirect calorimetry and an incremental bicycle protocol
Time frame: screening
body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference
Time frame: week 1
biochemical, proteomics and morphological analyses
Hasselt University
Other
The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise
Acronym: BALO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06576050
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT06709261
Body Weight, Nutrition Disorders
Orlando, Florida, United States
View Trial DetailsNCT05290064
Body Weight, Healthy Diet
Bethesda, Maryland, United States
View Trial DetailsNCT06077864
Body Weight, Nutrition Disorders
Birmingham, Alabama, United States
View Trial Details